Onconetix (ONCO) Other financing activities (2022 - 2026)
Onconetix (ONCO) posted quarterly Other financing activities of $384842.0 for Q1 2026, down 3.79% year-over-year from $400000.0 in Q1 2025, and up 284.84% quarter-over-quarter from $100000.0 in Q4 2025.
Onconetix (ONCO) Other financing activities (2022 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Other financing activities for 4 consecutive years, with $384842.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 3.79% year-over-year to $384842.0; the TTM figure through Mar 2026 stood at $484842.0 (up 297349.08% YoY), while the FY2025 annual figure was $500000.0, up 306648.47% from the prior year.
- Other financing activities rose to $384842.0 in Q1 2026 per ONCO's latest filing, from $100000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $778661.0 in Q4 2022 and bottomed at -$822937.0 in Q1 2022.
- Historically, Other financing activities has averaged $68187.8 across 4 years, with a median of $100000.0 in 2025.
- On a YoY basis, Other financing activities climbed as much as 1768.89% in 2025 and fell as far as 1768.89% in 2025.
- Onconetix's Other financing activities stood at $778661.0 in 2022, then slumped by 100.77% to -$5992.0 in 2024, then surged by 1768.89% to $100000.0 in 2025, then surged by 284.84% to $384842.0 in 2026.
- Business Quant data shows ONCO's Other financing activities at $384842.0 in Q1 2026, $100000.0 in Q4 2025, and -$100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 384,842.00 |
| Mar 31, 2026 | 384,842.00 |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | -5,992.00 |
| Dec 31, 2024 | -5,992.00 |
| Sep 30, 2024 | 5,992.00 |
| Sep 30, 2024 | 5,992.00 |
| Jun 30, 2024 | -399,837.00 |
| Jun 30, 2024 | -399,837.00 |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2022 | 778,661.00 |
| Dec 31, 2022 | 778,661.00 |